Bioxytran Launches Joint Venture with the Heme Foundation for Development of Universal Oxygen Carrier
18. Juli 2024 09:00 ET
|
BIOXYTRAN, INC.
The Heme Foundation and Bioxytran join forces to address the global blood supply shortage BOSTON, MASSACHUSETTS, July 18, 2024 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a...
LIXTE Biotechnology Holdings Announces the Passing of its Founder, John S. Kovach
09. Oktober 2023 08:30 ET
|
Lixte Biotechnology Holdings, Inc.
PASADENA, CA, Oct. 09, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage biotechnology company developing a novel...
Bioxytran Interview at the Emerging Growth Conference
04. Oktober 2023 09:00 ET
|
BIOXYTRAN, INC.
Thursday, October 5, 2023 10:15 am –10:45 am ESTSmall Pharma Strategy BOSTON, MASSACHUSETTS, Oct. 04, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage...
Bioxytran Announces Broad Spectrum Antiviral Activity Highlighted in ProLectin-M
14. September 2023 09:41 ET
|
BIOXYTRAN, INC.
BOSTON, MASSACHUSETTS, Sept. 14, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical stage biotechnology company developing oral drugs to treat COVID-19 and other viral...
Bioxytran Initiates a Registrational Trial of Oral ProLectin-M for Mild to Moderate COVID-19 Patients
08. August 2023 07:00 ET
|
BIOXYTRAN, INC.
BOSTON, MASSACHUSETTS, Aug. 08, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical stage biotechnology company developing oral drugs to treat COVID-19 and other viral...
Bioxytran Names Leslie Ajayi as Interim CMO and Head of the Medical Advisory Board
31. Juli 2023 07:00 ET
|
BIOXYTRAN, INC.
BOSTON, MASSACHUSETTS, July 31, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical stage biotechnology company developing oral drugs to treat COVID-19 and other viral...
Bioxytran Peer-Reviewed Journal in “Vaccines” Contains Mechanism Capable of Targeting Future COVID-19 Mutations
27. Juni 2023 07:00 ET
|
BIOXYTRAN, INC.
Complete elimination of viral load in 100% of patients at day 7 vs 6% in placebo (p=.001)Complete elimination of most symptoms by day 7Galectin antagonist acts as an entry inhibitor for use in...
Bioxytran Expands Institutional Investor Base with an additional $500,000 Equity Investment
12. Juni 2023 09:00 ET
|
BIOXYTRAN, INC.
- Funding in place to meet next regulatory milestone BOSTON, MASSACHUSETTS, June 12, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical stage biotechnology company...
Bioxytran Interview at the Emerging Growth Conference
03. April 2023 15:04 ET
|
BIOXYTRAN, INC.
Wednesday, April 5, 2023 10:50 am –11:20am ESTDiscussion of Peer Reviewed Article and Long COVID BOSTON, MASSACHUSETTS, April 03, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the...
ProLectin-M Demonstrates Significant Activity Against Influenza and Respiratory Syncytial Virus
28. Februar 2023 08:00 ET
|
BIOXYTRAN, INC.
Activity in Influenza and Respiratory Syncytial Virus highlights the broad- spectrum antiviral potential of ProLectin-M BOSTON, MASSACHUSETTS, Feb. 28, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC....